PhaseBio Pharmaceuticals, an early-stage biotech developing therapies to treat orphan diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Malvern, PA-based company was founded in 2002 and plans to list on the Nasdaq under the symbol PHAS. PhaseBio Pharmaceuticals filed confidentially on July 27, 2018. Citi, Cowen and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
